Vice President, Late Stage Ophthalmology - DME Emeryville, California

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development.

Our company is centered on our guiding principles. They direct every facet of our work, culture, hiring and drive to scale our world-class genetic medicines company.

4

DMT champions diversity, equity and inclusion every single day. Our employee‑led Diversity efforts are inspired by our guiding principles to focus awareness on social equity and create positive change not only within 4

DMT, but in our community  also seek to embrace our patient populations so we can help raise awareness.

We have had great success in our community partnering with charitable organizations.

We are focused on hiring, inspiring and supporting the best people in the industry who identify with our vision. We create an exciting, dynamic and collaborative environment that fosters dedication to visionary science and medicine, recognizes performance, offers generous benefits and provides challenging opportunities for career development. Join us in creating the future of genetic medicine.

Attention recruitment agencies: All agency inquiries are processed through 4

DMT’s internal Talent Acquisition team. Unsolicited resumes will not be accepted. The 4

DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4

DMT in the future.

4

DMT is a leading late‑stage biotechnology company advancing durable and disease‑targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi‑year sustained delivery of anti‑VEGF (aflibercept and anti‑VEGF‑C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections.

The Company’s lead indication for 4D-150 is wet age‑related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery.

Reporting to the Chief Medical Officer the VP Late Stage Ophthalmology provides strategic and operational leadership for the global development of ophthalmic genetic medicines in Drug Development.

We seek an experienced physician to play a critical role at 4

DMT as we spearhead the introduction of the first intravitreally delivered genetic medicines for the treatment of the most common causes of irreversible blindness. The VP, Late Stage Ophthalmology will be the primary point person for medical oversight of clinical studies with responsibilities to include medical monitoring, review and interpretation of clinical trial data, clinical trial design, protocol development, and drafting of key clinical documents such as protocol, CSR, briefing package, IND, NDA, BLA, etc.

This role will be responsible for timely execution of deliverables in close collaboration with relevant internal and external partners.

• Serve as the primary medical monitor for multiple ophthalmology clinical trials, providing expert oversight of patient safety, data integrity, and protocol adherence throughout study execution.
• Direct and mentor a team of medical monitors, ensuring high standards of medical oversight and data review, while maintaining personal accountability for real‑time monitoring activities and timely delivery of critical clinical trial…